ArticleNucleic acids research2022
COVID19db: a comprehensive database platform to discover potential drugs and targets of COVID-19 at whole transcriptomic scale.
Article in Nucleic acids research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Cross-Cell line transcriptome profiling reveals host-Virus interactions in monkeypox virus infection.Emerging microbes & infections · 2026Article
- JinHuangJieDu (JHJD) formula attenuates SARS-CoV-2 infection by interrupting RBD-ACE2 binding and HIF-1α-dependent inflammation.Frontiers in medicine · 2026Article
- Unveiling the role of PPIF and macrophage subtypes in LSCC progression via single-cell and exosome RNA sequencing.Scientific reports · 2025Article
- Link of TMPRSS2 expression with tumor immunogenicity and response to immune checkpoint inhibitors in cancers.Journal of translational medicine · 2025Article
- Altered ACE2 and interferon landscape in the COVID-19 microenvironment correlate with the anti-PD-1 response in solid tumors.Cellular and molecular life sciences : CMLS · 2024Article
- ExomiRHub: A comprehensive database for hosting and analyzing human disease-related extracellular microRNA transcriptomics data.Computational and structural biotechnology journal · 2024Article
- COVID-AMD database for coronavirus-infected animal models with comparative analysis tools.Scientific reports · 2024Article
- Bibliometric analysis of artificial intelligence in healthcare research: Trends and future directions.Future healthcare journal · 2024Article
- ExpOmics: a comprehensive web platform empowering biologists with robust multi-omics data analysis capabilities.Bioinformatics (Oxford, England) · 2024Article
- Overview of the Knowledge Management Center for Illuminating the Druggable Genome.Drug discovery today · 2024Review
- Systems biology approaches to identify driver genes and drug combinations for treating COVID-19.Scientific reports · 2024Article
- Regulatory variants of APOBEC3 genes potentially associate with COVID-19 severity in populations with African ancestry.Scientific reports · 2023Article
- Protein structure-based in-silico approaches to drug discovery: Guide to COVID-19 therapeutics.Molecular aspects of medicine · 2023Review
- Article
- DrugCentral 2023 extends human clinical data and integrates veterinary drugs.Nucleic acids research · 2023Article
- Applying the digital data and the bioinformatics tools in SARS-CoV-2 research.Computational and structural biotechnology journal · 2023Review
- CompCorona: A web application for comparative transcriptome analyses of coronaviruses reveals SARS-CoV-2-specific host response.Turkish journal of biology = Turk biyoloji dergisi · 2023Article
- Article
- The Spike Mutants Website: A Worldwide Used Resource against SARS-CoV-2.International journal of molecular sciences · 2022Article
- ML-DTD: Machine Learning-Based Drug Target Discovery for the Potential Treatment of COVID-19.Vaccines · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
14 authors.
Funding
Abstract
Many open access transcriptomic data of coronavirus disease 2019 (COVID-19) were generated, they have great heterogeneity and are difficult to analyze. To utilize these invaluable data for better understanding of COVID-19, additional software should be developed. Especially for researchers without bioinformatic skills, a user-friendly platform is mandatory. We developed the COVID19db platform (http://hpcc.siat.ac.cn/covid19db & http://www.biomedical-web.com/covid19db) that provides 39 930 drug-target-pathway interactions and 95 COVID-19 related datasets, which include transcriptomes of 4127 human samples across 13 body sites associated with the exposure of 33 microbes and 33 drugs/agents. To facilitate data application, each dataset was standardized and annotated with rich clinical information. The platform further provides 14 different analytical applications to analyze various mechanisms underlying COVID-19. Moreover, the 14 applications enable researchers to customize grouping and setting for different analyses and allow them to perform analyses using their own data. Furthermore, a Drug Discovery tool is designed to identify potential drugs and targets at whole transcriptomic scale. For proof of concept, we used COVID19db and identified multiple potential drugs and targets for COVID-19. In summary, COVID19db provides user-friendly web interfaces to freely analyze, download data, and submit new data for further integration, it can accelerate the identification of effective strategies against COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.